2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022818-19-DE (EUCTR) | 12/05/2011 | 21/02/2011 | Clinical Study of Dexpramipexole in Amyotrophic Lateral Sclerosis (ALS) | A randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Dexpramipexole in subjects with amyotrophic lateral sclerosis. - EMPOWER | Amyotrophic lateral sclerosis (ALS) MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Dexpramipexole Product Code: BIIB050 / KNS-760704 INN or Proposed INN: Dexpramipexole Dihydrochloride Other descriptive name: Dexpramipexole | Biogen Idec Limited | NULL | Not Recruiting | Female: yes Male: yes | 915 | United States;Canada;Spain;Ireland;Australia;Netherlands;Germany;United Kingdom;Sweden |